A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma - Wikidata - awgldk - TriplyDB

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

http://www.wikidata.org/entity/Q33412684

about

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Treatment of relapsed and refractory multiple myeloma Drugging the undruggables: exploring the ubiquitin system for drug development Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity European perspective on multiple myeloma treatment strategies in 2014 Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Trial Watch: Proteasomal inhibitors for anticancer therapy Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.Update on the optimal use of bortezomib in the treatment of multiple myeloma Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.Myeloma today: Disease definitions and treatment advances.Multiple myeloma in the marrow: pathogenesis and treatments.Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.Carfilzomib in multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.An update in treatment options for multiple myeloma in nontransplant eligible patients.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma Management of high-risk Myeloma: an evidence-based review of treatment strategies.The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.Treatment of Relapsed/Refractory Multiple Myeloma.

P2860

Q26740359-7BE49D18-5441-4190-A496-78E04CC65A32 Q26749180-053542FA-FB19-4652-A425-3D953B13A8A8 Q26752823-0A02B5B9-2CAA-4982-B76F-B63441492895 Q26771331-2F070E4D-6506-4BC4-A8A3-BC18C686691C Q27005966-6DCEFB7F-9B00-49CF-B236-093227E1851C Q27026478-64B4640D-7414-46A9-9832-26F2E2E558AC Q28082910-30DBFE37-43E3-4A75-8EFE-416614697D17 Q33423168-AF2C12E9-03F7-4C75-B786-E8503CF32C58 Q33425607-A03A9598-E6F6-49B8-9E9C-9F2B2A13C8F7 Q33437691-F76EC988-F61D-4C1F-96BB-C3019B387847 Q33437790-801E4909-0131-4951-BD61-2ACA4EEA4B5E Q33440007-E38173C5-D32F-4A5D-8DD7-7CDB1DF78DB9 Q33442923-B38BA7F6-B2E0-4841-96B2-36A99A9D0E83 Q33443411-569D624C-3455-42B1-9DB6-F20860FF01B4 Q34551324-E0B55544-8713-4587-AA6F-E680CD521C94 Q35764582-31644E5A-438A-412E-BEE2-F151A2431256 Q35809982-92FACC93-6AE3-4DEC-8599-E9376C6F82CE Q36274834-AB9F3896-332D-4F86-AC44-EAB46EA7ABD8 Q36470699-1AA8DCD8-13CF-41F4-B1D5-DC8DF9D5DBA3 Q36725401-AB6B3E6A-0879-4EC9-BBFB-AD060BC21829 Q36989576-5AFAFEB4-54A3-4049-A2CB-B858B514F607 Q37216292-ED24AA6D-A29B-4963-86CC-D7F8C22BAAC2 Q37373159-8FBE7086-963C-4186-B351-4AECB98D0C41 Q38244558-8FB3BD38-4156-4159-A3C5-08BDE26C4C9C Q38271032-6CABB5A9-C7FB-403E-8E0F-9B0184665D09 Q38400460-1FEF13DE-012C-4EF5-8707-FB3708598D6B Q38545607-BCEF9F95-8E0F-4B92-A8F9-EECF83F96EBC Q38561373-F83EF06B-B7B1-4EDA-A53C-97724F0E05E1 Q38630472-D18F75A6-D179-41EA-B4F9-A154AB1A3A41 Q38658649-F7C5519C-C2D2-47F2-B1BA-FE44853820A0 Q38672091-03184883-50F0-4095-AAB4-B902B47D7D5C Q38685108-21C7AADA-4BA9-4B13-9A1D-252BDD221791 Q38743857-83F8AC51-7942-4D1D-8D1A-AB774053933D Q38757067-10086D7E-4282-4161-BCD8-2C38272710CC Q38857256-70B85916-B0C2-41C8-94FD-4E96E84F876B Q38874675-84AB8414-B1CF-4FD1-A5BA-5D8268B3D700 Q38927463-4A3828B6-988C-4975-B0C7-3CD28A8A1BF0 Q38931762-42206F50-8B83-4358-9664-45B6D8D360F8 Q38937984-6C035562-E8B9-4FC6-831F-3D14F861269B Q38970597-C9602EA3-C947-4BB0-9791-1F8E0960B14C

P2860

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

http://www.wikidata.org/entity/Q33412684

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase 2 trial of lenalidomid ...... nd relapsed/refractory myeloma

@ast

A phase 2 trial of lenalidomid ...... nd relapsed/refractory myeloma

@en

type

label

A phase 2 trial of lenalidomid ...... nd relapsed/refractory myeloma

@ast

A phase 2 trial of lenalidomid ...... nd relapsed/refractory myeloma

@en

prefLabel

A phase 2 trial of lenalidomid ...... nd relapsed/refractory myeloma

@ast

A phase 2 trial of lenalidomid ...... nd relapsed/refractory myeloma

@en

P1433

Q33412684-E33F09A2-CC3D-4DCB-8856-727FBA6EA018

P1476

Q33412684-43FEB191-21AA-493D-88D5-E9DEED2E88E3

P2093

Q33412684-0589742A-6A82-4968-81E4-633AA450916B

Q33412684-0609EC46-3985-44A8-9D18-C3DDB03F035D

Q33412684-12B3E5B4-7E62-455F-BABC-861CE25822BE

Q33412684-41AD5694-091B-45A7-BCB0-6D3D34311567

Q33412684-46254BF1-A4B9-473E-BC99-DAAADD246253

Q33412684-5B92EC97-E3E9-4742-9A19-9A52FC079E5F

Q33412684-5CA634A0-02E7-4C46-8646-6EC99F0F521F

Q33412684-67049A3B-0DB1-4115-A3CE-A3119D0338E5

Q33412684-6E0C26ED-C298-46F1-A537-86556BFB2DDD

Q33412684-90940BB6-925B-47BC-9D05-BB91E0C9B236

P2860

Q33412684-1CBEDFE1-0266-4EEA-BB13-D2A3D59E7E80

Q33412684-259A24B1-A000-4248-A2BD-0BDC4DA474C8

Q33412684-25BB1E24-30CA-4757-8BBB-0EFEF592FEC1

Q33412684-2E2B8D98-0C9E-4C5E-ACD5-3B9556FF00BD

Q33412684-2F6F47C0-C269-49AA-B5F7-EE9CA4401295

Q33412684-40F11BC3-0A81-4865-A496-5946317C4C25

Q33412684-452C21F0-A573-4035-9E1E-A03E227E12AD

Q33412684-4781983A-3FD7-48A4-A1E8-23B1A90DB64E

Q33412684-496C0D7D-54EB-493B-AAD8-E7F47AD61DFE

Q33412684-4D2C11A5-FAAD-443D-989A-94C1C6521C7C

P304

Q33412684-E4A050BE-4C96-4CE9-A71A-836EADC10D13

P31

Q33412684-805F8F45-1AE4-4397-B125-A74C4A5630C7

P356

Q33412684-2127EBBC-097A-4102-A8AD-D0430D4D6C00

P407

Q33412684-C2357894-C4A4-4C47-92BE-B63917FB5CA2

P433

Q33412684-28D4760A-AFB0-42B9-858B-921882820A2C

P478

Q33412684-1CDEC2DF-551A-44F8-865A-FD5124EA26D2

P50

Q33412684-5BB7EF31-2257-4802-9225-A3682204A1B0

Q33412684-7EA40438-BF3B-4D89-9CFC-6E4A9D46BD3D

Q33412684-9D2C30E7-9DC2-4664-9E75-0E313F62FEC5

Q33412684-A2CEE4D9-E9C9-439F-B32F-8285555930FC

P577

Q33412684-34F8B47A-653F-4DF5-A407-EF3E271B0D88

P5875

Q33412684-DCE9B6F7-9098-4346-85BB-7ABEB9AF7A2E

P698

Q33412684-B5B5C4DE-0B60-4020-BED8-D40DD9CA3E1E

P921

Q33412684-2F0D5BE4-B263-4B9E-814F-F97A684D2C73

Q33412684-F22E448C-4322-4047-BBFC-1321EEE63989

P932

Q33412684-9A89D274-3C25-44C8-94AA-3A0680EB31D9

P356

BLOOD-2013-07-517276

P1433

P1476

A phase 2 trial of lenalidomid ...... nd relapsed/refractory myeloma

@en

P2093

Amitabha Mazumder

http://www.w3.org/2001/XMLSchema#string

Andrzej Jakubowiak

http://www.w3.org/2001/XMLSchema#string

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

David H Vesole

http://www.w3.org/2001/XMLSchema#string

Diane Warren

http://www.w3.org/2001/XMLSchema#string

Dixie-Lee Esseltine

http://www.w3.org/2001/XMLSchema#string

Dixil Francis

http://www.w3.org/2001/XMLSchema#string

Edie Weller

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

John Feather

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

P304

1461-1469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-07-517276

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2014-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259766050

http://www.w3.org/2001/XMLSchema#string

P698

24429336

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4123434

http://www.w3.org/2001/XMLSchema#string